FOI release

Safety concerns regarding Citalopram

Case reference FOI2025/00014

Received 4 January 2025

Published 26 January 2025

Request

Under the Freedom of Information Act, I would like to request the following information from the MHRA: 1. How many safety concerns were submitted per year to the MHRA via the Yellow Card Scheme from 2019 to 2024 concerning the drug, Citalopram (also known as Escitalopram)? 2. What safety concern is the most predominant that is reported about the drug, Citalopram (also known as Escitalopram)? 3. Is it safe to prescribe antidepressants (such as Citalopram) to patients under the age of 25, when there is a risk of suicide ideation?

Response

see attached

Documents

• FOI2025_00014 redacted for publication.pdf (119.0 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.